Lexeo Therapeutics LXEO 深 滬
已收盤 09-05 16:00:00 美东时间
5.02
+0.050
+1.01%
華盛通- 最 高5.28
- 今 開5.01
- 成交量 66.45万股
- 最 低 4.96
- 昨 收 4.97
- 總市值 1.67亿
- 52周最高 11.72
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.45
- 委 比 88.61%
- 總股本 3319.70万
- 歷史最高 22.33
- 量 比 2.22
- 振 幅 6.44%
- 歷史最低 1.45
- 每 手 1
- 風險率 2.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
09-05 02:50
Lexeo Therapeutics Q2 EPS $(0.60) Beats $(0.68) Estimate
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.68) by 11.76 percent. This is a 6.25 percent increase over losses of $(0.64) per share from
08-14 19:44
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
Lexeo Therapeutics reported progress on LX2006, receiving FDA Breakthrough Therapy designation for Friedreich ataxia, and参与了CDRP计划。LX2020在PKP2-ACM的试验中，8名患者已接受治疗，预计2025年下半年公布中期数据。公司完成8000万美元融资，现金储备达1.525亿美元，预计支持运营至2028年。新任CFO Louis Tamayo加入，推动临床和商业化计划。公司还与Perceptive Xontogeny Venture Funds和venBio Partners合作，开发非病毒RNA基因疗法，专注于心脏遗传疾病。
08-14 11:30
The FDA Grants Breakthrough Therapy Designation To Lexeo Therapeutics' LX2006 Based On Clinical Evidence Generated On Both Cardiac And Neurologic Measures Of Friedreich Ataxia
LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, intended to enable earlier patient access to therapies with expedited clinical
07-07 19:06
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Lexeo Therapeutics announced the U.S. FDA granted Breakthrough Therapy designation to LX2006 for Friedreich ataxia (FA) based on interim Phase I/II clinical data showing significant improvements in cardiac biomarkers and functional measures. LX2006 was also selected for the FDA's CMC Development and Readiness Pilot program to accelerate regulatory readiness and patient access. The designation highlights the potential of LX2006, with a focus on ad...
07-07 11:00
1. Lexeo Launches $40M RNA Heart Drug Venture With Backing From Top Biotech Investors
Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for
06-24 19:33
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
Lexeo Therapeutics announced a strategic partnership with leading investors to develop novel RNA-based therapies for genetic heart diseases, funding a new entity with up to $40 million. The partnership combines Lexeo's expertise in cardiac genetic medicines with a novel non-viral RNA delivery platform, aiming to advance cutting-edge cardiovascular science and address previously untreated conditions. The collaboration reflects a bet on the growing...
06-24 11:30
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
06-02 13:32
Lexeo Therapeutics raises $80M in private placement
Lexeo Therapeutics (NASDAQ:LXEO) has secured approximately $80M through a private placement with institutional and healthcare-focused investors. As part of the deal, Lexeo will sell 20.8M shares of co...
05-28 01:56
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Lexeo Therapeutics raised approximately $80 million through a private placement of common stock and warrants, with proceeds to fund operations into 2028. The offering, led by Frazier Life Sciences and Janus Henderson Investors, included participation from new and existing investors. Lexeo plans to use the funds to advance its clinical pipeline, including LX2006 for Friedreich ataxia cardiomyopathy. The deal is expected to close on May 28, 2025.
05-27 11:31
